The IPS-scale: A new soft tissue assessment scale for percutaneous and transcutaneous implants for bone conduction devices 1 
| INTRODUCTION
Percutaneous titanium implants for bone conduction devices (BCDs) have offered, since 1977, a solution for patients with hearing loss not treatable by conventional hearing aids, such as patients with chronic ear infections or microtia and/or ear canal atresia. 1 Percutaneous implants imply a continuous breach in the mechanical defensive barrier of the skin. To compensate for this breach, immunological mechanisms in the subcutaneous tissue surrounding the implant become more active. 2 Nonetheless, in a study, adverse skin reactions around the abutment were reported in 2.4%-38.1% of patients. 3 A grading system to standardise the reporting of soft tissue reactions around percutaneous implants for BCDs was introduced by Holgers et al. 4 Recently 
| METHODS
Ethical considerations: Ethical committee approval was not required for this evaluation.
With the widely used Holgers scale as reference, we interviewed surgeons and healthcare professionals experienced in postoperative care for BCD-implant recipients within our tertiary referral centre. three disadvantages, in addition to being subject to personal interpretations in indicating treatment. First, the current scale was originally developed to start evaluating the skin three months after implantation.
It therefore lacks the ability to describe complications in wound healing, such as (often minimal) dehiscence. Second, the scale lacks possibly the most important signal function, namely pain. Pain can result from skin infection, but may be caused by peri-implantitis, as is seen in dental implants. 9 Third, skin height is not incorporated in the Holgers scale. This is relevant in case a soft tissue preservation technique is applied, as skin can thicken around the abutment without infection signs, which can result in the inability to couple the sound processor, in the worst case requiring abutment change or skin revision.
| Requirements for a scale for transcutaneous implants
We evaluated possible pressure-related signs and symptoms based on our experience with postoperative skin inspection of patients with transcutaneous BCDs. Observations regarding skin integrity, colour and oedema were found to suggest intervention, such as reducing magnet strength. In addition, reporting of pain and numbness of the surgical flap area was found to be important factors influencing daily usage and patient satisfaction.
| Introduction of the IPS-scale
We aimed to incorporate all elements that are essential in soft tissue grading around implants into a new scale with three parts, namely I-scale (Inflammation-scale), P-scale (Pain-scale) and S-scale (Skin height/numbness-scale). These abbreviations have a different meaning based on implant type being scored, that is percutaneous or transcutaneous. A higher score reflects a more severe complication. The whole scale is presented in Figure 1 and is clarified below.
For percutaneous implants (the pIPS-scale), the Inflammationscale ranges from 0 to 4, comprising four dichotomous objective observations made by healthcare professionals, namely skin integrity, erythema, oedema and granulation tissue. The latter three are derived from the Holgers scale; however, skin integrity was added.
Skin integrity encompasses the observation of a blood crust or persistent minimal blood loss at the skin-abutment junction. These breaches of mechanical barrier function could make the peri-abutment soft tissue more prone to infections and should be included.
The Pain-scale reflects pain around the implant, developed immediately after surgery or after an initial postoperative pain-free period.
The Pain-scale ranges from 0 to 2 and is scored based on the presence, duration and increase of pain during abutment manipulation that is tightening of or tapping on the abutment. If increase in pain is observed after an initial postoperative pain-free period, it could indicate possible peri-implantitis, as seen in dental implants. 10 Early detection is crucial, because immediate treatment is necessary to avoid implant loss or elective removal because of chronic pain.
The introduction of soft tissue preservation surgery has resulted in an additional possible complication, that is skin thickening around the abutment without infection signs. The S-scale therefore represents skin height in relation to the abutment. It ranges from 0 to 2 and is scored based on the presence of skin thickening and the ability or inability to couple the sound processor onto the abutment, possibly requiring an abutment change or skin revision.
For transcutaneous implants (tIPS-scale), the Inflammation-scale ranges from 0 to 4 and comprises three observations, that is skin integrity, erythema and oedema. Granulation tissue cannot be observed in these implants. To retain similarity to the pIPS-scale, skin integrity weighs for two points, because lacerated skin is the result of prolonged excessive pressure, requiring immediate treatment.
Keypoints
• Developments in the design of percutaneous implants/ abutments for bone conduction devices, as well as surgical techniques, have resulted in other parameters becoming important in reporting soft tissue status.
• BCDs do not result in a permanent breach of the mechanical barrier of the skin. Nonetheless, soft tissue complications have been reported.
• To date, a standardised assessment scale for skin complications after transcutaneous BCD implantation is lacking.
• The new IPS-scale is a complete assessment scale for reporting soft tissue status in patients with either percutaneous or transcutaneous implants for BCDs.
• Standardised treatment advice is provided, based on the IPS-scale.
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Erythema and oedema weigh in for one point, because the observation of one of these two does not make treatment necessary per se.
The Pain-scale refers to pain at the implant site and ranges from 0 to 2. It is scored, unlike the pIPS-scale, based on the presence of pain together with the normal or diminished usage of the BCD. In our experience with transcutaneous implants, pain severity is closely related to a change in daily usage.
The S-scale refers, in transcutaneous implants, to the presence of skin numbness instead of skin height, but also ranges from 0 to 2. Prior to IPS-scoring in patients with a transcutaneous implant (tIPS-scale), it is important to verify normal daily usage, because most complications are pressure-related. In patients wearing the sound processor only a few hours a day, development of minor signs is, hence, the result of exceedingly high skin pressure during usage.
Although not yet evaluated, the tIPS-scale might also be useful as a standardised assessment scale for skin complications in patients with a cochlear implant or middle ear implant.
| Standardised treatment derived from the IPSscale
In contrast to the Holgers scale, we propose a standardised treatment advice for each IPS-scale (see Figure 1 ), based on our expert opinion. In patients with a percutaneous implant, an I 2-3 should be 
